These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. Lee HS; Min CK Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369 [TBL] [Abstract][Full Text] [Related]
6. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Nathwani N; Larsen JT; Kapoor P Curr Hematol Malig Rep; 2016 Apr; 11(2):127-36. PubMed ID: 26893062 [TBL] [Abstract][Full Text] [Related]
7. New developments in post-transplant maintenance treatment of multiple myeloma. Liu H; McCarthy P Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405 [TBL] [Abstract][Full Text] [Related]
8. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
10. Continuous treatment in multiple myeloma: the future? Vande Broek I; Jacobs P Transfus Apher Sci; 2013 Oct; 49(2):147-50. PubMed ID: 24074557 [TBL] [Abstract][Full Text] [Related]
11. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Palumbo A; Attal M; Roussel M Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441 [TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy for multiple myeloma. McCarthy PL; Palumbo A Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886 [TBL] [Abstract][Full Text] [Related]
15. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Kagoya Y; Nannya Y; Kurokawa M Leuk Res; 2012 Aug; 36(8):1016-21. PubMed ID: 22579366 [TBL] [Abstract][Full Text] [Related]
16. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT. Syed YY Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622 [TBL] [Abstract][Full Text] [Related]
17. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma. Highsmith KN; Chen SE; Horowitz S Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413 [TBL] [Abstract][Full Text] [Related]
18. Current therapeutic strategies for multiple myeloma. Torimoto Y; Shindo M; Ikuta K; Kohgo Y Int J Clin Oncol; 2015 Jun; 20(3):423-30. PubMed ID: 25855312 [TBL] [Abstract][Full Text] [Related]
19. An overview of the progress in the treatment of multiple myeloma. Kyle RA; Rajkumar SV Expert Rev Hematol; 2014 Feb; 7(1):5-7. PubMed ID: 24433105 [TBL] [Abstract][Full Text] [Related]
20. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]